Eukedos SpA

Eukedos SpA

MMIL:EUK
0.48
EUR
0.00
(0.00%)
18.42MMarket Cap
Eukedos SpA
MIL:EUK
(Euronext Milan)

Recent

price

0.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
93.33
74.67
4.8
3.94
3.37
3.23
2.21
2.27
2.3
2.35
2.07
1.99
2.07
2.17
2.27
2.33
- -
Revenue per Share
-20.59
-54.6
0.77
0.19
- -
-0.05
0.01
-0.09
0.05
0.03
-0.08
0.03
0.02
0.02
-0.02
-0.03
- -
Basic EPS, GAAP
12.62
-3.19
-0.09
0.25
-0.39
-0.11
-0.08
0.13
0.12
0.15
0.06
0.23
0.05
0.16
-0.58
0.02
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
47.37
-4.73
1.34
1.53
1.51
1.64
1.35
1.26
1.3
1.33
1.24
1.27
1.29
1.32
1.31
1.28
1.31
Book Value per Share
-23.84
-47.68
-0.44
0.02
0.09
0.7
0.58
0.48
0.53
0.55
0.43
0.45
0.48
0.49
0.42
0.39
0.42
Tangible Book Value per Share
1
1
18
18
18
18
23
23
23
23
23
23
23
23
23
23
23
Basic Weighted Avg Shares
81
62
85
70
59
59
50
52
52
53
47
45
47
49
52
53
- -
Sales/Revenue/Turnover
-11.06
-8
16.02
5.58
6.92
2.95
3.45
-2.11
4.17
8.14
2.84
10.05
8.18
10.54
9.79
10.21
- -
Operating Margin (%)
15
25
3
3
3
2
2
2
2
6
6
6
6
7
7
6
- -
Depreciation Expense
-18
-45
14
3
- -
-1
- -
-2
1
1
-2
1
- -
1
-1
-1
- -
Net Income, GAAP
- -
- -
0.31
214.99
113.06
- -
84.2
- -
41.33
61.99
- -
58.73
56.57
56.61
225.6
- -
- -
Effective Tax Rate (%)
-22.06
-73.12
16.04
4.77
0.08
-1.43
0.26
-4.17
1.96
1.12
-4.09
1.26
0.94
1.12
-1.01
-1.42
- -
Profit Margin (%)
-3
-41
- -
3
5
1
-4
-3
-4
-7
-14
-3
-6
-12
-18
-29
-20
Working Capital
67
31
43
37
38
12
17
15
14
100
92
104
105
98
93
111
118
LT Debt
50
- -
25
27
27
31
31
29
30
30
28
29
29
30
30
29
30
Total Equity
- -
- -
10.41
-3.62
-0.54
- -
0.51
- -
2.83
1.86
- -
1.42
1.22
1.65
-4.83
- -
- -
Return on Invested Capital (%)
- -
- -
20.51
0.92
-0.3
- -
0.64
- -
2.79
1.95
- -
1.41
1.37
1.66
-4.96
- -
- -
Return on Capital (%)
-35.6
- -
- -
13.11
0.18
-2.91
0.43
-7.27
3.52
2
-6.57
2
1.52
1.87
-1.75
-2.54
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'21
Dec'23
Jun'24
ST Debt
5
8
11
LT Borrowings
18
15
41
LT Finance Leases
82
82
76
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
26
21
18

Working Capital

EUR

•

in mil. unless spec.
Jun'21
Dec'23
Jun'24
Total Current Assets
11
9
17
Cash, Cash Equivalents & STI
4
2
5
Accounts Receivable, Net
4
5
7
Inventories
- -
- -
2
Total Current Liabilities
18
21
37
Payables & Accruals
- -
- -
- -
ST Debt
5
8
11
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.44%
0.62%
-2.47%
Free Cash Flow
-39.24%
-16.69%
-103.32%
Net Income, GAAP
-273.71%
-55.55%
42.94%
Sales/Revenue/Turnover
-0.81%
2.45%
2.35%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
49
2024
- -
- -
52
2025
- -
- -
53

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
-0.02
2025
- -
- -
-0.03

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Business
EuKedos S.p.A. operates as a leading Italian group in the managed care sector, specializing in the management of Residential Healthcare Facilities (RSA) for non-self-sufficient elderly individuals and vulnerable populations including disabled adults, those with cognitive decline, and psychiatric patients; it offers residential and day care social-health services through its subsidiary EDOS S.r.l., which manages approximately 1,400 beds across regions such as Lombardy, Piedmont, Abruzzo, Aosta Valley, and Emilia Romagna. The company, founded prior to its 2006 leadership transition under Chairman and CEO Carlo Iuculano and headquartered in Florence at Via Benedetto da Foiano 14, previously encompassed medical devices production including infusion therapy products, non-woven items, sterilization equipment for hospitals and pharmaceuticals, and turnkey furniture for healthcare facilities, though it has divested assets like Delta Med S.p.A. to Augens Capital. All operations and net sales remain concentrated in Italy within the healthcare facilities and services industry. Recent developments include approval of the 2024 financial report in June 2025 showing production value of EUR 51.6 million and a net loss of EUR 0.7 million, release of the semestral financial report as of June 30, 2025 in September 2025, appointment of Crowe Bompani as sustainability reviewer in May 2025, establishment of a Newco for real estate management related to RSA operations, and prior acquisitions such as a 40.23% stake in Poggio Imperiale S.r.l.; EuKedos functions as a subsidiary of La Villa S.p.A. with 654 employees.